Abstract: The technology described herein is directed to compositions comprising components of multi-component CALs or CARs, e.g., a TCR recognition domain; and one or both of: (a) an intracellular signaling domain; and (b) a first-type protein interaction domain. Further provided herein are methods for treating or preventing an autoimmune disease, a transplant rejection, or graft versus host disease.

Abstract: The technology described herein is directed to compositions comprising components of multi-component CALs or CARs, e.g., a TCR recognition domain; and one or both of: (a) an intracellular signaling domain; and (b) a first-type protein interaction domain. Further provided herein are methods for treating or preventing an autoimmune disease, a transplant rejection, or graft versus host disease.

Abstract: The technology described herein is directed to compositions comprising components of multi-component CALs or CARs, e.g., a TCR recognition domain; and one or both of: (a) an intracellular signaling domain; and (b) a first-type protein interaction domain. Further provided herein are methods for treating or preventing an autoimmune disease, a transplant rejection, or graft versus host disease.

Abstract: An object of the invention is to provide a novel pharmaceutical composition. The pharmaceutical composition of the disclosure contains a DNA encoding a suicide gene having at least one intron sequence. The intron sequence has a donor sequence or an acceptor sequence to be used in a tumor cell with abnormal splicing not in a normal cell. In a transcript of the DNA, the suicide gene is expressed when the intron is abnormally spliced and the suicide gene is not expressed when the intron is not abnormally spliced.

Abstract: The technology described herein is directed to compositions comprising components of multi-component CALs or CARs, e.g., a TCR recognition domain; and one or both of: (a) an intracellular signaling domain; and (b) a first-type protein interaction domain. Further provided herein are methods for treating or preventing an autoimmune disease, a transplant rejection, or graft versus host disease.

Abstract: An anaerobic composition comprising a polymerizable monomer having at least one ethylenic double bond, a free radical initiator and at least one azole compound.

Abstract: An anaerobically curing adhesive sealing composition comprising (A) a mono(meth)acrylate monomer represented by formula (I) ##STR1## wherein R.sub.1 represents a hydrogen atom or a methyl group; and R.sub.2 represents ##STR2## and (B) a (meth)acrylate prepolymer having a urethane structure in the main chain thereof and having an average molecular weight of 10,000 or more and further containing (C) a (meth)acrylate prepolymer having a urethane structure in the main chain thereof and an average molecular weight of at most 5,000. The sealing composition exhibits, upon curing, excellent elasticity and properties to follow an adherend while retaining excellent resistance to oil and heat as possessed by acrylate type reactive sealing compositions.

Abstract: A primer for .alpha.-cyanoacrylate-based resin compositions, which is disclosed herein, comprises (A) a compound selected from the group consisting of benzene ring compounds having aldehyde group and nitrogen or oxygen atom-containing heterocyclic compounds having aldehyde group, and (B) an organic amine compound. In bonding, coating or printing various non-polar or highly crystallized resins, the primer exhibits a high bonding strength by a simple procedure.